|Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA||CEO & Director||392.5k||N/A||1960|
|Dr. Ottavio V. Vitolo M.D.||Sr. VP, Head of R&D and Chief Medical Officer||330k||N/A||1972|
|Mr. Charles S. Ence||Chief Financial Officer||N/A||N/A||1965|
|Ms. Gina DiGuglielmo||VP & Head of Clinical Operations||N/A||N/A||N/A|
|Dr. Richard M. Mangano||Consultant||N/A||N/A||1950|
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.